Related Experiment Video
Updated: Feb 23, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Current status of MitraClip for patients with mitral and tricuspid regurgitation
Sidakpal S Panaich1, Mackram F Eleid1
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Abstract:
Mitral valve regurgitation (MR) affects approximately 4 million people in the United States alone, increasing in prevalence with age. Approved by the Food and Drug Administration (FDA) in October 2013, percutaneous edge-to-edge transcatheter mitral valve repair (also known as the MitraClip system) has been used in over 40,000 patients globally. Additionally, there is keen interest and early exploration into the use of MitraClip for treatment of severe symptomatic tricuspid regurgitation, another undertreated disease with significant morbidity and mortality. In this manuscript, we aim to review the current indications, procedural details as well as emerging indications for this novel technology.
More Related Videos
Related Concept Videos
Mitral Regurgitation III: Medical Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Regurgitation IV: Nursing Management
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation I: Introduction
Mitral Stenosis III: Medical Management

